Sham Controlled Trial of Rapid Induction Percutaneous Tibial Nerve Stimulation

  • STATUS
    Recruiting
  • End date
    Dec 30, 2023
  • participants needed
    64
  • sponsor
    William Beaumont Hospitals
Updated on 4 March 2022
antimuscarinic
percutaneous tibial nerve stimulation
bladder symptoms

Summary

The aim of this study is to determine the efficacy of an accelerated course for percutaneous tibial nerve stimulation (PTNS) induction to treat overactive bladder symptoms. The standard 12 weekly induction treatments may be a patient burden and a more rapid induction may speed up symptomatic improvement.

Description

Overactive bladder (OAB) is a common condition with a prevalence ranging from 5.9% to 16.9% in the United States and has been found to increase with age. OAB has a negative impact on health related quality of life (QoL), Per American Urological Association (AUA) / Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) guidelines, PTNS is a third line recommendation for OAB along with onabotulinumtoxinA (BTX) injection and sacral neuromodulation. In the single sham-controlled trial (SUmiT: n=220), Peters et al reported that 54.5% of PTNS subjects had moderately or markedly improved bladder symptoms on global response assessments (GRA) compared to 20.9% of sham subjects (p <0.001). PTNS subjects also had statistically significant improvements in frequency, nighttime voids, voids with moderate to severe urgency and urge urinary incontinence (UUI) episodes compared to sham. There is also early data from an implanted chronic tibial nerve stimulation lead study that shows a minimum of 8 hours of tibial nerve stimulation a day results in significant improvement in incontinence episodes per day at one week. Our study will test the concept of whether the PTNS effect is dose (total time of treatment) sensitive, and whether expanding the dosage of each treatment, i.e. from 30 minutes to 2 hours, will provide significant clinical improvement after a one week induction course.

Details
Condition Overactive Bladder
Treatment Sham Treatment, PTNS treatment
Clinical Study IdentifierNCT03547518
SponsorWilliam Beaumont Hospitals
Last Modified on4 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Women and men > 18 years of age
Self-reported failed conservative care of behavioral modifications and/or oral medications
An above normal urinary frequency as recorded on initial 3-day voiding diary
Self-reported bladder symptoms greater than or equal to 3 months
On a stable dose of antimuscarinics/beta-3 agonists for greater than or equal to 4 weeks, and willing to remain on the medication for the duration of the study OR discontinued antimuscarinics/beta-3 agonists for greater than or equal to 2 weeks
Capable of giving informed consent
Ambulatory and able to use toilet independently without difficulty
Capable and willing to follow all study-related procedures

Exclusion Criteria

Pregnant or planning to become pregnant during study duration
Diagnosis of neurogenic bladder
Botox use in bladder or pelvic floor muscles within past 12 months
Pacemakers or implantable defibrillators
Current urinary tract infection
Active use of neuromodulation in any other form. If patient has InterStim, must be turned off for 2 weeks for a washout period and remain off during the entirety of the study
Current use of Transcutaneous Electrical Nerve Stimulation (TENS) in pelvic region, back or legs
Previous PTNS treatment who received greater than 6 treatments. Those who have received less than 6 treatments will be allowed to screen if the last treatment was at least 6 months prior to screening
Use of investigational drug/device therapy within past 4 weeks
Participation in any clinical investigation involving or impacting gynecologic, urinary or renal function within past 4 weeks
Current or past history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results
Note: For the sake of preserving scientific integrity, one or more of the
eligibility criteria have been left off the list posted while the trial is
ongoing. A full list of eligibility criteria will be posted upon completion of
the trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note